<DOC>
	<DOCNO>NCT00248638</DOCNO>
	<brief_summary>Relative glutamine ( GLN ) deficiency may contribute morbidity mortality surgical intensive care unit ( SICU ) patient . During critical illness , GLN utilization immune system , gut mucosa tissue exceed endogenous production plasma GLN concentration decrease , may contribute cellular dysfunction increase nosocomial infection risk mortality . Conventional GLN-free parenteral nutrition ( PN ) limit impact SICU outcomes repair GLN deficit . Our recent pilot data show GLN dipeptide-supplemented PN decrease nosocomial infection improve clinical outcome SICU patient . The process benefit poorly understood , animal human data suggest GLN treatment correlate ) up-regulation cytoprotective molecule blood tissue [ e.g , GSH , specific heat shock protein ( HSPs ) GLN ] ; b ) improve epithelial barrier defense immune cell number function . Properties L-GLN limit provision solution , GLN dipeptide alanyl-GLN ( AG ) confers stability solubility PN ( AG-PN ) . We propose multicenter , double-blind , randomize , control phase III trial base pilot data test hypothesis AG-PN improve clinical outcome SICU patient require PN cardiac , vascular colonic operation . Subjects receive either standard GLN-free PN isocaloric , isonitrogenous , AG-PN enteral feed establish . Specific Aim 1 determine whether AG-PN decrease hospital mortality , nosocomial infection important index morbidity . Specific Aim 2 obtain novel , mechanistically relevant observational data Aim 1 subject whether AG-PN ) increase serial blood level GSH , HSP-70 -27 , GLN ; b ) decrease presence serum bacterial product flagellin LPS adaptive immune response mediator ; c ) improve key index innate/adaptive immunity . This study design delineate clinical benefit major new nutrition support strategy high-risk SICU patient .</brief_summary>
	<brief_title>Efficacy Mechanisms GLN Dipeptide SICU</brief_title>
	<detailed_description>Overview : Relative deficiency glutamine ( GLN ) appear contribute morbidity mortality surgical intensive care unit ( SICU ) patient , conventional nutrition support repair deficit . GLN requirement increase critical illness utilization immune system , gut mucosa tissue exceed endogenous production . GLN depletion condition may contribute hospital morbidity mortality . Conventional parenteral nutrition ( PN ) contain GLN thus prevent GLN depletion catabolic patient . However , pilot study report strongly suggest GLN-supplemented PN improve metabolic clinical outcome critically ill patient . Underlying mechanisms GLN action poorly understood , may involve systemic upregulation cytoprotective molecule glutathione ( GSH ) , specific heat shock protein ( HSP ) GLN , improve gut barrier defense , improve innate and/or adaptive immune function . Properties L-GLN limit provision PN , dipeptide alanyl-glutamine ( AG ) confers stability solubility PN solution . The P.I . 's pilot study demonstrate marked decrease nosocomial infection , improved index organ function , possible decrease hospital mortality SICU patient receive AG-supplemented PN ( AG-PN ) versus standard , GLN-free PN ( STD-PN ) . We propose multi-center , double-blind , control , Phase III trial , base pilot study , determine effect parenteral GLN important clinical outcome patient require SICU care PN cardiac , vascular colonic surgery . We also propose obtain needed hypothesis-generating , descriptive data Aim 1 study subject inform subsequent , truly mechanistic study GLN action animal human model surgical critical illness . Study subject randomize intent-to-treat basis receive AG-PN isonitrogenous , isocaloric STD-PN enteral feeding establish . Hypotheses : 1 . SICU patient receive PN supplement GLN dipeptide ( AG-PN ) demonstrate improve clinical outcome compare patient receive STD-PN . 2 . Administration AG-PN Aim 1 study subject : ) increase serial blood level specific cytoprotective molecule improve systemic redox status ; b ) associate decreased serum positivity bacterial product flagellin lipopolysaccharide ( LPS ) adaptive immune response mediator ; c ) improve key index innate/adaptive immunity . Specific Aims : Aim 1 : To perform Phase III randomize control trial ( RCT ) determine whether AG-PN decrease hospital mortality , nosocomial infection , index hospital morbidity versus STD-PN SICU patient . The study test whether AG-PN : decrease hospital mortality incidence nosocomial infection ( primary endpoint ) SICU patient cardiac , vascular colonic surgery . We also determine whether AG-PN decrease total hospital infection , bloodstream infection ( BSI ) , infection due Staphylococcus aureus fungal specie , number day patient require mechanical ventilation , SICU total hospital length stay 6-month mortality rate ( secondary endpoint ) . Aim 2 : To determine Aim 1 study subject whether AG-PN : ) increase systemic blood concentration cytoprotective molecule GSH , HSP-70 , HSP-27 GLN improve systemic GSH cysteine redox status ; b ) associate decreased serum positivity bacterial product flagellin LPS titer anti-flagellin anti-LPS immunoglobulin M ( IgM ) , immunoglobulin A ( IgA ) immunoglobulin G ( IgG ) ; c ) improve key index innate/adaptive immune cell function .</detailed_description>
	<mesh_term>Critical Illness</mesh_term>
	<criteria>Inclusion criterion : 1 ) A sign inform consent place patient 's chart ; 2 ) The patient least 18 90 year age time surgery ; 3 ) The patient body mass index ( BMI ) &lt; 40 kg/m2 prior surgery ; 4 ) The patient currently require SICU care within 14 day postoperative one follow open ( nonlaparoscopic ) surgical procedure : coronary artery bypass graft ( CABG ) , cardiac valve , vascular ( nonneurosurgical ) , esophageal gastrointestinal resection esophagus , stomach , small bowel , colon and/or rectum ) , operation identify source peritonitis evidence bowel perforation ( without bowel resection ) ; 5 ) The patient require central venous PN 7+ subsequent day entry clinical basis≠ ; 6 ) There central venous access administration study PN ; 7 ) The patient 's primary physician ( ) allow investigative team manage study PN enteral feeding current hospitalization . 1 ) The patient pregnant ; 2 ) The patient clinical sepsis [ define unstable blood pressure despite pressor support AND mean arterial pressure ( MAP ) &lt; 60 mm Hg least 3 consecutive reading within 3hour period 24 hour prior study entry ; 3 ) ) The patient current malignancy require surgery GLND qualifying operation OR b ) patient currently receive active regimen chemotherapy and/or radiotherapy treat previously diagnose malignancy† ; 4 ) The patient history seizure preexist seizure disorder ; 5 ) The patient current encephalopathy* ; 6 ) The patient known history cirrhosis OR serum total bilirubin level ≥ 10.0 mg/dL ) ; 7 ) The patient history chronic renal failure require dialysis , significant renal dysfunction ( define serum creatinine &gt; 2.5 mg/dL receive continuous renal replacement therapy ( CRRT ) patient require acute hemodialysis postoperatively ; 8 ) The patient concomitant burn trauma injury ; 9 ) The patient previously undergone organ transplantation ; 10 ) patient history HIV/AIDS ; 11 ) The patient receive investigational drug within 60 day prior study entry ; 12 ) The patient receive enteral parenteral enteral feeding enrich arginine and/or glutamine within 30 day prior study entry ; 13 ) The patient unable unwilling participate study procedure longitudinal blood draw patient followup visit , etc . *Encephalopathy GLND diagnose nonchemically sedate patient primary critical care physician neurologist consultant define either comatose state OR severe abnormality diagnose electroencephalogram ( EEG ) , OR follow criterion meet : ) patient go sleep arousable verbal painful stimulus ; open eye spontaneously ( decreased level consciousness ) ; b ) patient exhibit severe confusion complete disorientation arouse ( disorientation ) ; c ) patient exhibit severe lethargy bizarre behavior ( behavioral dysfunction ) ; ) patient exhibit inability cooperate , asterixis , ataxia , clonus , decortication , decerebration , seizure , rigidity ( severe neuromuscular dysfunction ) . † Patients malignant metastasis terminal untreatable carcinoma exclude per operational definition agree upon Data Safety Monitoring Board ( DSMB ) . ≠ Please note patient SICU initial PN hang time .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>